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The never-ending controversy of rate vs. rhythm control in
atrial ﬁbrillation [AF] continues to bother physicians and
cardiologists all over the world. The majority of trials investi-
gating this issue recruit patients with no structural heart disease
[SHD]. Conclusive data with regard to rate vs. rhythm control in
AF patients with SHD are lacking. Presence of SHD inﬂuences
the treatment strategy as well as treatment options which are
limited. Although guidelines recommend rhythm control
strategy in patients with SHD to minimize symptoms and
thromboembolic events, they recommend rate control in
patients with valvular heart disease because of low likelihood
of maintaining sinus rhythm in the long run.1 The guidelines do
advice long-term anticoagulation with conventional older oral
anticoagulants for all patients with AF and valvular heart
disease to prevent stroke.1 However, in developing countries
including India, many patients with rheumatic mitral stenosis
(MS) or regurgitation with chronic AF are not on chronic oral
anticoagulation [warfarin (Coumadin) or Acenocoumarol/
Nicoumalone (Acitrom), the two most commonly used oral
anticoagulants] therapy due to various reasons.2,3
The new generation novel anticoagulants are more
pharmacologically stable with a predictable dose–effect
response and do not require monitoring, although no trials§ This editorial is pertaining to the article: Effect of heart rate control 
atrial ﬁbrillation – A Pilot Study.as yet have established their use in valvular AF even though
they have proved to be better than warfarin for non-valvular
AF patients.1 The recent RE-ALIGN dabigatran study, the ﬁrst
trial of novel oral anticoagulant in patients with mechanical
heart valves was stopped due to high bleeding and thrombo-
embolic episodes in the dabigatran group.4
2. Problems with warfarin and related oral
anticoagulants
Warfarin is very effective in preventing stroke in AF patients,
reducing stroke by 68% (when compared to placebo), 40%
(when compared to aspirin), and reducing mortality by 26%.5
However, it has been noted that about 60% of patient do not
get warfarin when indicated, around 50% of patient discon-
tinue especially in the developing world, and of those on
regular therapy, only 50% are in therapeutic range.2,3 Impor-
tant issues with older oral anticoagulants are slow onset,
prolonged action, and unpredictable dose–effect relationship
with a narrow therapeutic index requiring close monitoring
and adjustment of the dose. The narrow therapeutic range
results in non-protection from thrombus formation/stroke if
an international normalized ratio (INR) is <2 or results in
minor or major bleeding if the INR is >4. In addition, oral
anticoagulation therapy has variable pharmacokinetics dueon coagulation status in patients of rheumatic mitral stenosis with
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interactions, and ﬁnally cost factor, wherein many patients
from low socio-economic strata are unable to afford either the
drug/INR cost or sometimes travel expenses to a clinic where
INR is checked.2,3
There are few anticoagulation issues related particularly to
Indian patients.2,3 Indians have a dietary habit which
increases warfarin–food interaction, especially increased use
of green leafy vegetables causing low INR values. Indians
consume over the counter medications like non-steroidal anti-
inﬂammatory drugs or herbal products/foods, which are
available without prescription from pharmacies, as well as
indulge in extensive use of antibiotics like metronidazole or
macrolides which can increase INR levels and bleeding risk.
Some patients are on concomitant anti-tuberculous drugs like
isoniazid or rifampicin, which can also result in under- or over-
anticoagulation. Indians generally have low body weight and
are more prone to bleeding. Increasing epidemic of smoking
causes enzyme induction and lowering of INR. Another issue
in India is prothrombin time/INR monitoring. The majority of
towns including suburbs of large cities lack proper laboratories
with standardized measurement of prothrombin time/INR.2,3
3. Hypercoagulable state in rheumatic MS with
AF: is it rate-related?
Rheumatic MS is known to be a hypercoagulable state, both
systemic as well as regional (left atrial), more so when AF sets
in.6,7 Advances in biochemical assay have led to the develop-
ment of sensitive methods for determining levels of markers
which reﬂect thrombin activity [thrombin-antithrombin III
complex (TAT), prothrombin fragment 1 + 2 (PF 1 + 2), ﬁbrino-
peptide A/B, ﬁbrinogen], ﬁbrinolytic activity [plasminogen
activator inhibitor (PAI-1), plasmin-alpha 2-plasmin inhibitor
complex (PIC), D-dimer, tissue plasminogen activator (tPA)],
and platelet activity [platelet factor 4 (PF 4), beta-thromboglo-
bulin, P-selectin, von Willebrand factor (vWF)] in vivo.
In an interesting study, Asakura et al. measured TAT and PF
1 + 2 in 83 patients with AF.6 Increased levels of plasma TAT
and PF 1 + 2 were more frequently observed in patients with AF
and associated MS than in patients with AF alone.6 They
concluded that AF per se is a moderately hypercoagulable state
but with associated MS, it becomes an extremely hypercoagu-
lable state. In vivo activation of blood coagulation was more
effectively controlled in patients receiving warfarin than in
those taking aspirin.6 In addition, increased regional left atrial
(LA) hypercoagulability has been implicated in LA thrombus
formation and systemic embolism in MS.7 In a study, LA PF 1
+ 2 level exceeded the peripheral venous level in patients with
a normal INR when compared to patients with a prolonged INR
on warfarin.7 These results suggest that anticoagulation with
warfarin in MS not only reduces systemic coagulation activity,
but also is associated with a greater reduction in LA
coagulation activity.
All these studies prove the beneﬁcial effect of warfarin in
MS patients with AF in preventing stroke. However, not all
patients in developing countries are able to take warfarin due
to various reasons mentioned previously. Is there an alterna-
tive strategy or an add-on strategy in these patients to preventstroke? A few years ago, there was a study by Atak et al. who
hypothesized that hypercoagulable state in MS with AF may be
rate-related.8 They measured plasma levels of PF 1 + 2, TAT,
and PAI-1 in 54 patients with MS and AF. In patients with
resting heart rates <100 beats per minute, plasma concentra-
tions of PF 1 + 2, TAT, and PAI-1 were lower than those patients
with heart rate >100 beats per minute. However, there were no
further studies done on this subject, until Jamal et al. in this
issue of Indian Heart Journal are publishing a study involving 100
participants with 70 patients and 30 controls.9 They deﬁne
controlled ventricular rate (<100 beats per min) in a more
objective way than Atak et al. based on a 24-h Holter monitoring
rather than one-off ECG. They convincingly demonstrate that
plasma concentrations of TAT, PF 1 + 2, and PAI-1 were
signiﬁcantly elevated in patients with heart rate more than
100 and a signiﬁcant correlation was found between heart rate
and three coagulation factors. Further, the heart rate was found
to be an independent predictor of systemic coagulation
activation. The mechanism proposed to explain this prothrom-
botic state in MS is an obstruction to ﬂow across the mitral valve,
decreased diastolic ﬁlling time when heart rate is high with
increase in transmitral gradient/LA pressure and blood stasis
which leads to activation of platelets, the coagulation system
and predisposition to thrombus formation.9
4. Can strict rate control of <100 beats per
minute be made an obligatory strategy to reduce
hypercoagulable state in rheumatic MS with AF?
Yes, from previous studies including the one by Jamal et al., if
the mechanisms proposed based on ventricular rate alone are
in fact operative in producing a hypercoagulable state, it could
be concluded that strict rate control below 100 beats per
minute could reduce hypercoagulable state in MS patients
with AF and should be made an obligatory treatment strategy,
even though larger studies involving more patients are needed
to convince all physicians and cardiologists. Another intrigu-
ing question is whether a heart rate of 60–80 beats per minute
further reduces the procoagulant factors. Interestingly, Erdo-
gan et al. recently reported that strict heart rate control
attenuates prothrombotic state and platelet activity in
patients with non-valvular permanent AF.10 Many prothrom-
botic factors were found to be high in patients with uncon-
trolled ventricular rate. They even repeated the coagulation
markers after 1 month of strict rate control and found that all
markers were signiﬁcantly reduced. Furthermore, in another
invasive study, Lim et al. sought to assess the effect of AF on
atrial thrombogenesis in humans by determining the impact
of rate and rhythm.11 They studied 55 patients with AF who
underwent catheter ablation while in sinus rhythm; AF was
induced in twenty patients while twenty others underwent
atrial pacing at 150 beats per minute and ﬁfteen patients were
retained as controls. Platelet activation increased signiﬁcantly
in both the AF and pacing groups, but decreased in control
patients. Thrombin generation increased speciﬁcally in the LA
compared with the periphery in both the AF and pacing
groups, but decreased in control patients indicating that rapid
atrial rates and AF in humans both result in increased platelet
activation and thrombin generation.
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state, both systemic as well as regional (left atrial), leading to
thrombus formation. This needs to be tackled in two ways. One
strategy is by oral anticoagulation whenever possible and
second by strict ventricular rate control below 100 beats per
minute to reduce prothrombotic factors and preventing
thrombus formation. The second approach is very appropriate
in developing countries including India, wherein monitoring
prothrombin time/INR is difﬁcult due to various reasons. In the
scenario where both approaches can be applied, it might be
reasonable to combine an appropriately aggressive oral
anticoagulation stratagem with that of a strict ventricular-
rate control one to achieve incremental beneﬁt.
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